文献速递药物不良反应与药物警戒

新冠疫苗接种对法国自发药物警戒报告的影响

Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
PubMed 文献 · Drug Saf · 2023-11-05

该研究基于法国药物警戒数据库2018年1月至2022年4月的170,294份非新冠疫苗相关不良反应报告,采用中断时间序列分析评估2021年1月启动的新冠疫苗接种活动的影响。结果显示接种活动开始后非新冠疫苗相关月均报告数下降约35.0%,即时水平下降658.0份(p<10^-3),斜率下降50.0份/月(p<10^-3),主要源于医疗专业人员报告减少,可能导致其他药物安全信号检测能力受损。

要点

  • 新冠疫苗接种活动开始后,非疫苗相关ADR月报告数下降约35%。
  • 下降主要来自医疗专业人员报告,严重与非严重报告均减少。
  • 抗肿瘤/免疫调节药及血液系统药物严重报告可能增加。

核心结论

  • 新冠疫苗接种活动对非新冠疫苗相关ADR报告产生显著影响,月均报告下降约35.0%,可能导致其他药物安全监测信息丢失。

研究设计与样本

  • 基于法国药物警戒数据库的时间序列分析,纳入2018年1月1日至2022年4月30日期间170,294份非新冠疫苗相关ADR报告,以2021年1月为干预点进行中断时间序列分析。

主要发现

  • 非新冠疫苗相关报告共170,294份,其中严重报告77,067份(45.3%),医疗专业人员报告146,683份(86.1%)。
  • 接种活动开始后月报告数即时水平下降658.0份(p<10^-3),斜率下降50.0份/月(p<10^-3)。
  • 医疗专业人员报告即时水平下降739.2份(p<10^-3),斜率下降39份/月(p<10^-2)。
  • 严重报告即时水平下降402.3份(p<10^-3),非严重报告下降311.9份(p=10^-2)。
  • 按ATC一级分类,所有药物报告下降模式相似,但抗肿瘤和免疫调节药(ATC L)及血液系统药物(ATC B)的严重报告可能增加。

临床怎么用

  • 临床药学智能体应关注新冠疫苗接种期间非疫苗药物ADR报告减少可能导致的监测盲区,加强其他药物安全信号识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2021, the massive Covid-19 vaccination campaign in France was accompanied by an intensified pharmacovigilance monitoring of their potential adverse drug reactions. The importance of this reporting might have led to an important selective reporting and overloading of Pharmacovigilance Centres, delaying the recording of some reports in the national pharmacovigilance database. In this context, we aimed to evaluate the impact of the Covid-19 vaccination campaign in France and related reports on spontaneous reporting of adverse drug reactions that were not related to the Covid-19 vaccine. METHODS: We performed time-series analyses considering the monthly number of adverse drug reactions reported between January 1, 2018 and April 30, 2022 using the French Pharmacovigilance database. The impact of the Covid-19 vaccination campaign on the monthly reporting not Covid-19 vaccine related was estimated using interrupted time-series. January 2021, marking the start of the campaign, was the intervention date in the models. Analyses were run globally first considering all adverse drug reaction reports, and second according to notifier type and to case seriousness. RESULTS: We included 170,294 reports registered in the French Pharmacovigilance database between January 1, 2018 and April 30, 2022 that were not Covid-19 vaccine-related. Among these, 77,067 (45.3%) were serious and 146,683 (86.1%) had been reported by health care professionals. The campaign start was associated with a nearly 35.0% decrease in average monthly reporting that was not Covid-19 vaccine-related, with a significant level decrease in the monthly number of reports of -658.0 (p < 10-3) immediately after the vaccination campaign start and a subsequent slope decrease of -50.0 (p < 10-3). This decrease was mainly due to a significant level and slope decrease (level: -739.2 p < 10-3; slope: -39 [p < 10-2]) for health care professional reports. A similar level decrease was found for the monthly number of both serious and non-serious reports (-402.3, p < 10-3; and -311.9, p = 10-2, respectively). According to the ATC 1 level, the decrease in the monthly number of reports showed similar patterns for all drugs. However, a potential increase in the number of serious reports suspecting antineoplastic and immunomodulating drugs (ATC L) or drugs targeting blood was observed (ATC B). CONCLUSION: Our study showed a significant impact of the Covid-19 campaign vaccination in the reporting of adverse drug reactions that were not Covid-19 vaccine-related, of roughly 35%. This leads to a loss of information regarding the monitoring of drug safety that could have impacted the system capacity to detect safety signals for drugs other than Covid-19 vaccines.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. de Germay S, Singier A, Salvo F, et al. Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France. Drug Saf. 2023. PMID: 37926785. doi:10.1007/s40264-023-01359-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。